JPS5951547B2 - benzofuran derivatives - Google Patents

benzofuran derivatives

Info

Publication number
JPS5951547B2
JPS5951547B2 JP51000351A JP35176A JPS5951547B2 JP S5951547 B2 JPS5951547 B2 JP S5951547B2 JP 51000351 A JP51000351 A JP 51000351A JP 35176 A JP35176 A JP 35176A JP S5951547 B2 JPS5951547 B2 JP S5951547B2
Authority
JP
Japan
Prior art keywords
hydroxy
value
propoxybenzofuran
ethyl
isopropylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51000351A
Other languages
Japanese (ja)
Other versions
JPS5283733A (en
Inventor
清 伊藤
三生 林田
輝雄 中西
一彦 木村
美知子 永原
雅彦 池本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP51000351A priority Critical patent/JPS5951547B2/en
Priority to CA257,342A priority patent/CA1089866A/en
Priority to GB3161576A priority patent/GB1502248A/en
Priority to DE19762635064 priority patent/DE2635064C2/en
Priority to CH997876A priority patent/CH628338A5/en
Priority to FR7624676A priority patent/FR2328463A1/en
Priority to BE169780A priority patent/BE845156A/en
Priority to NL7610426A priority patent/NL7610426A/en
Publication of JPS5283733A publication Critical patent/JPS5283733A/en
Priority to CH529981A priority patent/CH633785A5/en
Publication of JPS5951547B2 publication Critical patent/JPS5951547B2/en
Expired legal-status Critical Current

Links

Description

【発明の詳細な説明】 本発明は医薬として有用な新規なベンゾフラン誘導体に
関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel benzofuran derivatives useful as pharmaceuticals.

本発明の化合物は一般式 RHC□CH2■HCH2NHR1(I)(式中、Rは
水素原子、低級アルキル基またはフェニル基、R1は低
級アルキル基であり、置換プロボキシ基はベンゾフラン
環の3、4、、5、6または7位の任意の位置に置換し
ている)で示されるベンゾフラン誘導体1およびそれら
の酸付加塩である。
The compound of the present invention has the general formula RHC□CH2■HCH2NHR1(I) (wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, R1 is a lower alkyl group, and the substituted proboxyl group is 3, 4, , substituted at any position of 5, 6 or 7) and acid addition salts thereof.

前記一般式1のRに含まれる低級ツルキル基としてはメ
チル、エチル、n−プロセル、イソプロピル、n−ブチ
ル、イソブチル、sec−ブチルなどの炭素数が1〜4
個の直鎖状または分岐鎖状アルキル基があげられる。
The lower turkyl group contained in R in the general formula 1 is a group having 1 to 4 carbon atoms such as methyl, ethyl, n-procell, isopropyl, n-butyl, isobutyl, sec-butyl, etc.
straight-chain or branched alkyl groups.

またR1で表わされる低級アルキル基としてはメチル、
エチル、n−プロピル、イソプロピル、n−ブチル、イ
ソブチル、sec−ブチル、tert−ブチルなどの炭
素数が1〜4個の直鎖状または分岐鎖状アルキル基があ
げられ、とくに炭素数が3〜4個の分岐鎖状アルキ.ν
基が好ましい。酸付加塩としては塩酸塩、硫酸塩、硝酸
塩などの無機酸塩あるいは酢酸塩、シユウ酸塩、コハク
酸塩、リンゴ酸塩などの有機酸塩があげられる。
In addition, the lower alkyl group represented by R1 is methyl,
Examples include straight-chain or branched alkyl groups having 1 to 4 carbon atoms, such as ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl, particularly those having 3 to 4 carbon atoms. 4 branched alkyls. ν
Groups are preferred. Examples of acid addition salts include inorganic acid salts such as hydrochloride, sulfate, and nitrate, and organic acid salts such as acetate, oxalate, succinate, and malate.

本発明の化合物はアドレナリン性β一受容体遮断作用を
示し、しかも該作用を示す既知化合物より低毒性であり
、不整脈、狭心症などの心臓病あるいは高血圧症などの
予防薬および治療薬として有用である。本発明のベンゾ
フラン誘導体1は一般式 (式中、R’は低級アルキル基、低級アルコキシ基また
はフエニル基であり、R1は前記に同じものを表゛わし
、一゛置換プロポキシ基はベンゾフラン環の3、4、5
.、6または7位の任意の位置に置換している》で示さ
れるベンゾフラン誘導体()またはその酸付加塩を還元
することによりえられる。
The compounds of the present invention exhibit adrenergic β-receptor blocking activity, and are less toxic than known compounds that exhibit this activity, and are useful as preventive and therapeutic agents for heart diseases such as arrhythmia and angina pectoris, and hypertension. It is. The benzofuran derivative 1 of the present invention has the general formula (wherein R' is a lower alkyl group, a lower alkoxy group, or a phenyl group, R1 represents the same as described above, and the monosubstituted propoxy group is the 3-substituted propoxy group of the benzofuran ring. , 4, 5
.. , substituted at any position of 6 or 7) or an acid addition salt thereof.

前記一般式()のR,に含まれる低級アルキル基として
はメチル、エチル、n−プロピル、イツプロピル、n−
ブチル、イソブチル、Sec−ブチルなどの炭素数l〜
4個の直鎖状または分岐鎖状アルキル基があげられ、低
級アルコキシ基としてはメトキシ、エトキシ、プロボキ
シ、イソプロボキシ、n−ブトキシ、イソブトキシSe
c−ブトキシ、Tert−ブトキシなどがあげられる。
前記ベンゾフラン誘導体()の酸付加塩としてはベンゾ
フラン誘導体(I)のばあいと同様なものがあげられる
。前記還元反応は通常の還元剤を用いて通常の還元条件
下で好適に実施される。たとえば、つぎのごとき還元方
法が好適なものとしてあげられる。(1)還元剤として
水素化アルミニウムリチウム、水素化ホウ素ナトリウム
、ジポランなどを用いる方ム反応溶媒としては通常メタ
ノール、エタノール、ジオキサン、テトラヒドロフラン
およびこれらの混合溶媒が用いられる。(2)還元剤と
して金属または金属アルコキシドを用いる方法。
The lower alkyl group included in R in the general formula () is methyl, ethyl, n-propyl, itpropyl, n-
Number of carbon atoms such as butyl, isobutyl, Sec-butyl, etc.
Four straight-chain or branched alkyl groups are mentioned, and lower alkoxy groups include methoxy, ethoxy, proboxy, isoproboxy, n-butoxy, and isobutoxySe.
Examples include c-butoxy and tert-butoxy.
Examples of the acid addition salts of the benzofuran derivative () include those similar to those for the benzofuran derivative (I). The reduction reaction is suitably carried out using a conventional reducing agent under conventional reducing conditions. For example, the following reduction method is suitable. (1) A method using lithium aluminum hydride, sodium borohydride, diporan, etc. as a reducing agent. As a reaction solvent, methanol, ethanol, dioxane, tetrahydrofuran, or a mixed solvent thereof is usually used. (2) A method using a metal or metal alkoxide as a reducing agent.

とくにアルミニウムエトキシド、アルミニウムイソプロ
ポキシド、アルミニウムTert−ブトキシドが好まし
く用いられ、反応溶媒としてはアルコール類または炭化
水素類が,用いられる。(3)接触還元方法。
In particular, aluminum ethoxide, aluminum isopropoxide, and aluminum tert-butoxide are preferably used, and alcohols or hydrocarbons are used as the reaction solvent. (3) Catalytic reduction method.

触媒としてはラネーニツケル、パラジウム炭素などの通
常の接触還元触媒がいずれも用いられ、常圧、加圧いず
れも採用しうる。反応溶媒としては通常メタノール、エ
タノール、ジオキサンー・テトラヒドロフラン9シクロ
ヘキサン、水およびこれらの混合溶媒が用いられる。(
4)還元剤としてウサギ、ハムスター、マウス、ラツト
などの肝臓、腎臓、血液、腸管などに広く分布する酵素
(アロマテイツクアルデヒドケトンレグクターゼ)を用
い、適当なPHと温度条件下で還元する方法。
As the catalyst, any of the usual catalytic reduction catalysts such as Raney nickel and palladium on carbon can be used, and either normal pressure or pressurized pressure can be used. As the reaction solvent, methanol, ethanol, dioxane-tetrahydrofuran, 9-cyclohexane, water, and a mixed solvent thereof are usually used. (
4) As a reducing agent, an enzyme (aromatic aldehyde ketone reductase) that is widely distributed in the liver, kidney, blood, intestinal tract, etc. of rabbits, hamsters, mice, rats, etc. is used, and reduction is performed under appropriate pH and temperature conditions. Method.

なお前記還元反応はベンゾフラン誘導体(ρアルカリ水
溶液を放置することによつてもおこる。
Note that the above reduction reaction also occurs when the benzofuran derivative (rho alkali aqueous solution is allowed to stand).

前記還元反応において、ベンゾフラン誘導体偶)のR’
が低級アルキル基およびフエニル基のばあいは、Rが相
当する低級アルキル基およびフエニル基のベンゾフラン
誘導体(I)がえられ、R’が低級アルコキシ基のばあ
いはRが水素原子のベンゾフラン誘導体(I)がえられ
る。えられたベンゾフラン誘導体(I)は常法にしたが
い、たとえば適当な有機溶媒中で相当する酸を作用する
ことにより酸付加塩にかえることができる。
In the reduction reaction, R' of the benzofuran derivative
When R is a lower alkyl group and a phenyl group, a benzofuran derivative (I) in which R is a corresponding lower alkyl group and a phenyl group is obtained, and when R' is a lower alkoxy group, a benzofuran derivative (I) in which R is a hydrogen atom is obtained. I) can be obtained. The obtained benzofuran derivative (I) can be converted into an acid addition salt according to a conventional method, for example, by reacting with the corresponding acid in a suitable organic solvent.

本発明の化合物には1〜4個の不整炭素が存在し、立体
異性体が存在するっ したがつて、本発明は個々の立体
異性体およびそれらの混合物に関することになる。本発
明において出発物質として用いるペンゾフラン誘導体(
)は、たとえば特公昭50−2σ0’63号公報に記載
された方法、すなわち一般式(式中、R’は前記に同じ
ものを表わし、水酸基はベンゾフラン環の3,4,5,
6または7位の任意の位置に置換している)で示される
ベンゾフラン誘導体(自)にエピクロルヒドリンを反応
させ、えられた一般式(式中、R′は前記に同じものを
表わし、2,3−エポキシプロポキシ基はベンゾフラン
環の3,4,5,6または7位の任意の位置に置換して
いる)で示されるベンゾフラン誘導体(5)に一般式H
2NR}(式中、R1は前記に同じものを表わす)で示
される第1級アミンを反応させることによつて容易にえ
られる。
Since there are 1 to 4 asymmetric carbon atoms in the compounds of the invention and stereoisomers exist, the invention relates to the individual stereoisomers and mixtures thereof. Penzofuran derivatives used as starting materials in the present invention (
), for example, by the method described in Japanese Patent Publication No. 50-2σ0'63, that is, the general formula (wherein R' represents the same as above, and the hydroxyl group is 3,4,5,
A benzofuran derivative (substituted at any position of 6 or 7) is reacted with epichlorohydrin to obtain a general formula (wherein R' represents the same as above, and 2,3 - The epoxypropoxy group is substituted at any position of the 3, 4, 5, 6 or 7 position of the benzofuran ring).
2NR} (in the formula, R1 represents the same thing as above).

本発明のベンゾフラン誘導体(1)およびその酸付加塩
はいずれも新規化合物であつて、すぐれた薬理作用を有
し医薬として有用である。
Both the benzofuran derivative (1) and its acid addition salt of the present invention are new compounds, have excellent pharmacological effects, and are useful as medicines.

たとえば、これらの化合物は低酸素またはイソプロテノ
ール負荷における心電図を改善するばかりでなく、イソ
プロテノールによつて生ずる収縮力および心拍数の増加
および血圧降下を抑制し、したがつてアドレナリン性β
一受容体遮断作用を示し、不整脈、狭心症などの心臓病
あるいは高血圧症などの予防薬および治療薬として有用
である。またこれらの化合物は既知のアドレナリン性β
一受容体遮断剤よりも低毒性である。本発明の化合物は
1日あたり約10〜200即程度の投与量で投与される
ことによりそのすぐれた薬効を発揮する。
For example, these compounds not only improve the electrocardiogram in hypoxia or isoprotenol loading, but also suppress the isoprotenol-induced increases in contractile force and heart rate and the drop in blood pressure, thus reducing adrenergic β
It exhibits receptor blocking action and is useful as a preventive and therapeutic agent for heart diseases such as arrhythmia and angina pectoris, and hypertension. These compounds also have known adrenergic β
It is less toxic than single receptor blockers. The compounds of the present invention exhibit their excellent medicinal efficacy when administered in doses of about 10 to 200 doses per day.

投与方法としては経口、皮下注射、静脈注射のいずれも
採用しうる。本発明の化合物は製剤時に通常用いられる
キヤリヤ一を用いて常法にしたがつて製剤化することに
よつて、カプセル剤、錠剤、顆粒剤、注射薬にすること
ができる。
The administration method may be oral, subcutaneous injection, or intravenous injection. The compounds of the present invention can be formulated into capsules, tablets, granules, and injections by conventional methods using carriers commonly used in formulations.

つぎに本発明を実施例および試験例をあげて説明する。Next, the present invention will be explained with reference to Examples and Test Examples.

実施例 1 〔2−(1−ヒドロキシ)エチルーJヨ黶i2ヒドロキシ
−3−Sec−ブチルアミノ)プロポキシベンゾフラン
〕2−アセチルーJヨ黶i2−ヒドロキシ−3一Sec−
ブチルアミノ)プロポキシベンゾフラン0.61f!を
ジオキサン20aと水2m1の混合液に溶かし、氷冷下
に水素化ホウ素ナトリウム0.059を加え、ついで室
温下に1時間攪拌した。
Example 1 [2-(1-Hydroxy)ethyl 2-hydroxy-3-Sec-butylamino)propoxybenzofuran]2-acetyl-3-Sec-
Butylamino) propoxybenzofuran 0.61f! was dissolved in a mixture of dioxane 20a and water 2 ml, and 0.059 ml of sodium borohydride was added under ice cooling, followed by stirring at room temperature for 1 hour.

えられた反応液を氷水100a中に注ぎ、これを塩析下
に酢酸エチルで抽出し、有機層を無水硫酸ナトリウムで
脱水後溶媒を減圧下に留去した。えられた残渣をベンゼ
ン一石油エーテル(3:2容量比)から再結晶して融点
88〜90℃の白色粉末状の化合物を0.549えた。
えられた化合物について元素分析値、赤外線吸収スペク
トル、薄層クロマトグラム(Rf値)およびNMRスペ
クトル(δ値)を測定してこの化合物が2−(1−ヒド
ロキシ)エチルーJヨ黶i2−ヒドロキシ−3−Se′c
−ブチルアミノ)プロポキシベンゾフランであることを
確認した。
The obtained reaction solution was poured into ice water 100a, which was extracted with ethyl acetate while salting out.The organic layer was dehydrated over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was recrystallized from benzene/petroleum ether (3:2 volume ratio) to yield 0.549 g of a white powdery compound with a melting point of 88-90°C.
Elemental analysis values, infrared absorption spectra, thin layer chromatograms (Rf values) and NMR spectra (δ values) of the obtained compound were measured to determine whether the compound was 2-(1-hydroxy)ethyl-2-hydroxy- 3-Se′c
-butylamino)propoxybenzofuran.

なお、Rf値は担体としてタルク社製のキーセルゲルH
F254を用い、ベンゼンリエタノール:28%アンモ
ニア水=6:4:0.3で展開したばあいの値である(
以下同様)。またδ値は重クロロホルム中で100MH
zで測定した値である(以下同様)。以下に元素分析値
、特性赤外線吸収スペクトル(単位:Cfn−1)、R
f値およびδ値を示す。なおδ値のあとのカツコ内の数
値は順にプロトン数、多重度を表わす(以下同様)。元
素分析値:Cl7H25O4Nとして 理論値(へ):C66.42H8.2ON4.56実測
値%:C66.7lH8.3ON432特性赤外線吸収
スペクトル:ν0H3375,3325 νNH325O νC=Cl627,l62O,l589.ノ Rf値: 0.41 δ値: 0.92(3H,t),1.11(3H,d),1.5
0(2H,q),1.65(3H,d),2.50〜3
.20(6H,m),4.20(3H,m),5.06
(1H,q),6.64(1H,S),6.80〜7.
40(3H,m)実施例 2 〔2−(1−ヒドロキシ)エチルーJヨ黶i2−ヒドロキ
シ−3−Tert−ブチルアミノ)プロポキシベンゾフ
ラン〕2−アセチルーJヨ黶i2−ヒドロキシ−3一Te
rt−ブチルアミノ)プロポキシベンゾフラン0.61
9をジオキサン20m1と水2!!L!,の混合液に溶
かし、氷冷下に水素化ホウ素ナトリウム0.059を加
え、ついで室温下に1時間攪拌した。
Note that the Rf value is determined using Kiesel Gel H manufactured by Talc as a carrier.
This is the value when F254 is used and developed with benzene triethanol: 28% aqueous ammonia = 6:4:0.3 (
Same below). Also, the δ value is 100MH in deuterochloroform.
This is the value measured at z (the same applies below). Below are elemental analysis values, characteristic infrared absorption spectrum (unit: Cfn-1), R
The f value and δ value are shown. Note that the numbers in brackets after the δ value represent the number of protons and the multiplicity (the same applies below). Elemental analysis value: Cl7H25O4N Theoretical value (to): C66.42H8.2ON4.56 Actual value %: C66.7lH8.3ON432 Characteristic infrared absorption spectrum: ν0H3375,3325 νNH325O νC=Cl627,l62O,l589. Rf value: 0.41 δ value: 0.92 (3H, t), 1.11 (3H, d), 1.5
0 (2H, q), 1.65 (3H, d), 2.50-3
.. 20 (6H, m), 4.20 (3H, m), 5.06
(1H, q), 6.64 (1H, S), 6.80-7.
40(3H,m) Example 2 [2-(1-Hydroxy)ethyl-Jyo-i2-hydroxy-3-Tert-butylamino)propoxybenzofuran]2-acetyl-Jyo-i2-hydroxy-3-Te
rt-butylamino)propoxybenzofuran 0.61
9 with 20ml of dioxane and 22ml of water! ! L! , and added 0.059 g of sodium borohydride under ice cooling, followed by stirring at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理し、えられた残
渣をベンゼンから再結晶して融点126〜127℃の白
色粉末状の化合物を0.499えた。元素分析値:Cl
7H2,O4Nとして理論値2:C66.42H8.2
ON4.56実測値O:C66.28H8.37N4.
6l特性赤外線吸収スペクトル:ν0H3375 νNH32OO νC=Cl635,l6O5,l595Rf値: 0.33 δ値: 1.14( 9H,S)、1.63( 3H,d)、2
.60〜3.20( 5H,m),4.19( 3H,
m),5.04( IH,q),6.62(IH,S)
,6.80〜7.50(3H,m)実施例 3〔2 −
(1−ヒドロキシ)エチルーJヨ黶i2−ヒドロキシ−3
−イソプロピルアミノ)プロポキシベンゾフラン〕2−
アセチル− 7 −( 2 −ヒドロキシ−3−イソプ
ロピルアミノ)プロポキシベンゾフラン0.589をジ
オキサン201n1!と水2“の混合液に溶かし、氷冷
下に水素化ホウ素ナトリウム0.059を加え、ついで
室温下に1時間攪拌した。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from benzene to obtain 0.499% of a white powdery compound with a melting point of 126-127°C. Elemental analysis value: Cl
Theoretical value 2 as 7H2, O4N: C66.42H8.2
ON4.56 Actual value O: C66.28H8.37N4.
6l characteristic infrared absorption spectrum: ν0H3375 νNH32OO νC=Cl635,l6O5,l595Rf value: 0.33 δ value: 1.14 (9H,S), 1.63 (3H,d), 2
.. 60-3.20 (5H, m), 4.19 (3H,
m), 5.04 (IH, q), 6.62 (IH, S)
, 6.80-7.50 (3H, m) Example 3 [2-
(1-Hydroxy)ethyl-Jyo-i2-Hydroxy-3
-isopropylamino)propoxybenzofuran]2-
Acetyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran 0.589 to dioxane 201n1! The mixture was dissolved in a mixture of 2" and 2" of water, and 0.059% of sodium borohydride was added under ice cooling, followed by stirring at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理し、えられた残
渣をベンゼンー石油エーテル( 1:1容量比)から再
結晶して融点77〜81℃の白色粉末状の化合物を0.
539えた。元素分析値:C,6H23O4Nとして 理論値%:C65.5lH7.9ON4.78実測値%
:C65.43H7.94N4.83特性赤外線吸収ス
ペクトル:ν0H3375 νNH335O νC=Cl627,l6OO,l589Rf値: 0.25 δ値: 1.06( 6H,d),1.58( 3H,d),2
.60〜3.00(3H,m),3.43(3H,S)
,3.90〜4.30(3H,m),4.98(IH,
S),6.67(IH,S),6.75〜 7.15(
3H,m)実施例 4 〔2 −(1−ヒドロキシ)エチル− 7 −( 2
ーヒドロキシ−3−イソプロピルアミノ)プロポキシベ
ンゾフラノ塩酸塩〕実施例3でえた2 −(1−ヒドロ
キシ)エチル− 7 −( 2 −ヒドロキシ−3−イ
ソプロピルアミノ)プロポキシベンゾフラン0.1gを
エチルエーテル10ゴに溶かし、これに塩酸ガスを吹込
み、えられた白色沈澱を炉取し、ついで酢酸エチルから
再結晶して融点83〜88℃の無色針状の塩酸塩を0.
089えた。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from benzene-petroleum ether (1:1 volume ratio) to obtain a white powdery compound with a melting point of 77-81°C.
I got 539. Elemental analysis value: C, 6H23O4N Theoretical value %: C65.5lH7.9ON4.78 Actual value%
:C65.43H7.94N4.83 Characteristic infrared absorption spectrum: ν0H3375 νNH335O νC=Cl627,l6OO,l589Rf value: 0.25 δ value: 1.06 (6H, d), 1.58 (3H, d), 2
.. 60-3.00 (3H, m), 3.43 (3H, S)
, 3.90-4.30 (3H, m), 4.98 (IH,
S), 6.67 (IH, S), 6.75-7.15 (
3H,m) Example 4 [2-(1-hydroxy)ethyl-7-(2
-Hydroxy-3-isopropylamino)propoxybenzofurano hydrochloride] 0.1 g of 2-(1-hydroxy)ethyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran obtained in Example 3 was added to 10 g of ethyl ether. The resulting white precipitate was collected in an oven and then recrystallized from ethyl acetate to obtain colorless needle-like hydrochloride with a melting point of 83-88°C.
Got 089.

実施例 5 〔2 −(1−ヒドロキシ)エチル− 7 −( 2
−ヒドロキシ− 3 −イソプロピルアミノ)プロポキ
シベンゾフラン酢酸塩〕実施例3でえた2 −(1−ヒ
ドロキシ)エチル− 7 −( 2 −ヒドロキシ−3
−イソプロピルアミノ)プロポキシベンゾフラン0.7
59を酢酸エチル20!!Leに溶かし、これに酢酸2
00mfiとエーテル10ゴを加え、一夜冷所に放置し
て融点104〜107℃の無色針状の酢酸塩を0.89
えた。
Example 5 [2-(1-hydroxy)ethyl-7-(2
-hydroxy-3-isopropylamino)propoxybenzofuran acetate] 2-(1-hydroxy)ethyl-7-(2-hydroxy-3 obtained in Example 3)
-isopropylamino)propoxybenzofuran 0.7
59 to ethyl acetate 20! ! Dissolve in Le, add 2 acetic acid to this
Add 0.0mfi and 10g of ether and leave in a cool place overnight to dissolve 0.89% of colorless needle-like acetate with a melting point of 104-107°C.
I got it.

実施例 6〔2 −(1−ヒドロキシ)エチル− 4
−( 2 ーヒドロキシ−3−イソプロピルアミノ)プ
ロポキシベンゾフラン〕2−アセチル− 4 −( 2
−ヒドロキシ−3−イソプロピルアミノ)プロポキシ
ベンゾフラン0.589をジオキサン20ゴと水2“の
混合液に溶かし氷冷下に水素化ホウ素ナトリウム0.0
59を加え、ついで室温下に1時間攪拌した。
Example 6 [2-(1-hydroxy)ethyl-4
-(2-hydroxy-3-isopropylamino)propoxybenzofuran]2-acetyl-4-(2
-Hydroxy-3-isopropylamino)propoxybenzofuran 0.589 is dissolved in a mixture of 20 g of dioxane and 2" of water and 0.0 g of sodium borohydride is dissolved under ice-cooling.
59 was added thereto, and the mixture was stirred at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理し、えられた残
渣をエーテルー石油エーテル( 1:1容量比)から再
結晶して融点64〜66℃の白色粉末状の化合物を0.
319えた。元素分析値:Cl6H23O3Nとして 理論値W:C65.5lH7.9ON4.78実測値O
:C65.73H7.9lN4.59特性赤外線吸収ス
ペクトル:ν0H3350 νNH328O νC=Cl6O9,l595R f値: 0.27 δ値: 1.26( 6H,d),1.73( 3H,d),2
.50〜3.20(6H,m),4.00〜4.20(
3H,m),5.04(IH,q),6.64(IH,
dd)、6.68(IH,S),7.1〜7.4(2H
,m)実施例 7 〔2 −(1−ヒドロキシ)エチル− 5 −( 2
一ヒドロキシ−3−Secブチルアミノ)プロポキシベ
ンゾフラン〕2−アセチル−5−(2−ヒドロキシ−3
−Sec−ブチルアミノ)プロポキシベンゾフラン0.
619をジオキサン20aと水2aに溶かし6氷冷下に
水素化ホウ素ナトリウム0.059を加え、ついで室温
下に1時間撹拌した。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from ether-petroleum ether (1:1 volume ratio) to obtain a white powdery compound with a melting point of 64-66°C.
I got 319. Elemental analysis value: Cl6H23O3N Theoretical value W: C65.5lH7.9ON4.78 Actual value O
:C65.73H7.9lN4.59 Characteristic infrared absorption spectrum: ν0H3350 νNH328O νC=Cl6O9,l595R f value: 0.27 δ value: 1.26 ( 6H, d), 1.73 ( 3H, d), 2
.. 50-3.20 (6H, m), 4.00-4.20 (
3H, m), 5.04 (IH, q), 6.64 (IH,
dd), 6.68 (IH, S), 7.1-7.4 (2H
, m) Example 7 [2-(1-hydroxy)ethyl-5-(2
monohydroxy-3-Secbutylamino)propoxybenzofuran]2-acetyl-5-(2-hydroxy-3
-Sec-butylamino)propoxybenzofuran 0.
619 was dissolved in 20a of dioxane and 2a of water, and 0.059% of sodium borohydride was added while cooling with ice, followed by stirring at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理し、えられた残
渣をアセトン一石油エーテル(1:1容量比)から再結
晶して融点94〜96℃の白色粉末状の化合物を0.4
59えた。元素分析値:Cl7H25O4Nとして 理論値(有):C66.42H8.2ON4.56実測
値%:C66.78H7.98N4.49特性赤外線吸
収スペクトル:ν0H3360 νNH328O νC=Cl6l2,l6O8R f値: 0.38 δ値: 0.99(3H,t),1.09(3H,d),1.4
7(2H,d),1.61(3H,d),2.50〜3
.20(6H,m),3.90〜4.20(3H,m)
,5.01(1H,q),6.57(1H,S),6.
86(1H,d),6.99(1H,dd),7.39
(1H,d)実施例 8 〔2−(1−ヒドロキシ)エチル−6−(2ーヒドロキ
シ−3−Tert−ブチルアミノ)プロポキシベンゾフ
ラン〕2−アセチル−6−(2−ヒドロキシ−3−Te
rトブチルアミノ)プロポキシベンゾフラン0.61f
Iをジオキサン20aと水2aの混合液に溶かし、氷冷
下に水素化ホウ素ナトリウム0.059を加え、ついで
室温下に1時間攪拌した。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from acetone-petroleum ether (1:1 volume ratio) to obtain a white powdery compound with a melting point of 94-96°C. 4
I got 59. Elemental analysis value: Theoretical value as Cl7H25O4N: C66.42H8.2ON4.56 Actual value %: C66.78H7.98N4.49 Characteristic infrared absorption spectrum: ν0H3360 νNH328O νC=Cl6l2,l6O8R f value: 0.38 δ value : 0.99 (3H, t), 1.09 (3H, d), 1.4
7 (2H, d), 1.61 (3H, d), 2.50-3
.. 20 (6H, m), 3.90-4.20 (3H, m)
, 5.01 (1H, q), 6.57 (1H, S), 6.
86 (1H, d), 6.99 (1H, dd), 7.39
(1H, d) Example 8 [2-(1-hydroxy)ethyl-6-(2-hydroxy-3-Tert-butylamino)propoxybenzofuran]2-acetyl-6-(2-hydroxy-3-Te
rTobutylamino)propoxybenzofuran 0.61f
I was dissolved in a mixture of dioxane 20a and water 2a, and 0.059% of sodium borohydride was added under ice cooling, followed by stirring at room temperature for 1 hour.

えられた反応液を実施例1と同様にして処理し、えられ
た残渣をベンゼンから再結晶して融点129〜131℃
の白色粉末状の化合物を0.54f!えた。元素分析値
:Cl,H25O4Nとして理論値%:C66.42H
8.2ON4.56実測値(へ):C66.54H8.
l3N4.8O特性赤外線吸収スペクトル:ν0H33
25 νNH3275 νC=Cl628,l588Rf 値: 0.27 δ値: 1.16(9H,S),1.62(3H,d),2.6
0〜3.00(5H,m),3.90〜4.10(3H
,m),5.030H,q),6.58(1H,S),
6.93(1H,dd),7.07(1H,d),7.
47(1H,d)実施例 9 〔2−(1−ヒドロキシ)ブチルーJヨ黶i2−ヒドロキ
シ−3−Tert−ブチルアミノ)プロポキシベンゾフ
ラン〕2−ブチリルーJヨ黶i2−ヒドロキシ−3一Te
rt−ブチルアミノ)プロポキシベンゾフラン0.66
gをジオキサン201n1と水2aの混合液に溶かし、
氷冷下に水素化ホウ素ナトリウム0.059を加え、つ
いで室温下に1時間撹拌した。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from benzene to give a melting point of 129 to 131°C.
0.54f of white powdery compound! I got it. Elemental analysis value: Cl, theoretical value % as H25O4N: C66.42H
8.2ON4.56 Actual value (to): C66.54H8.
l3N4.8O characteristic infrared absorption spectrum: ν0H33
25 νNH3275 νC=Cl628, l588Rf Value: 0.27 δ value: 1.16 (9H, S), 1.62 (3H, d), 2.6
0-3.00 (5H, m), 3.90-4.10 (3H
, m), 5.030H, q), 6.58 (1H, S),
6.93 (1H, dd), 7.07 (1H, d), 7.
47 (1H, d) Example 9 [2-(1-Hydroxy)Butyl-J 2-Hydroxy-3-Tert-butylamino)propoxybenzofuran]2-Butyryl-J 2-Hydroxy-3-Te
rt-butylamino)propoxybenzofuran 0.66
Dissolve g in a mixture of dioxane 201n1 and water 2a,
0.059 ml of sodium borohydride was added under ice cooling, and the mixture was stirred at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理して黄色油状物
の化合物を0.43f1えた。元素分析値:Cl,H2
,O4Nとして 理論値(へ):C68.O3H8.7lN4.l8実測
値(へ):C68.57H8.63N4.24特性赤外
線吸収スペクトル:ν0H3375 νNH33OO νC=Cl622,l6O2,l59ORf値: 0.35 δ値: 0.93(3H,t),1.11(9H,S),1.4
6(2H,m),1.91(2H,q),2.75(2
H,d),3.70(3H,S),4.23(3H,m
),4.81(1H,t),6.60(1H,S),6
.75〜7.40(3H,m)実施例 10〔2−(1
−ヒドロキシ)エチルーJヨ黶i2−ヒドロキシ−3−イ
ソプロピルアミノ)プロポキシベンゾフラン〕2−アセ
チルーJヨ黶i2−ヒドロキシ−3−イソプロピルアミノ
)プロポキシベンゾフラン0.619をウサギ肝臓ホモ
ジネート80f1の1059遠心処理上清からえた酵素
分画と、PH7.4、温度37℃で補酵素(NADPH
生成系)とともに30分間インキユベートした。
The obtained reaction solution was treated in the same manner as in Example 1 to obtain 0.43 fl of a yellow oily compound. Elemental analysis value: Cl, H2
, Theoretical value (to) as O4N: C68. O3H8.7lN4. l8 Actual value (to): C68.57H8.63N4.24 Characteristic infrared absorption spectrum: ν0H3375 νNH33OO νC=Cl622,l6O2,l59ORf value: 0.35 δ value: 0.93 (3H, t), 1.11 (9H , S), 1.4
6 (2H, m), 1.91 (2H, q), 2.75 (2
H, d), 3.70 (3H, S), 4.23 (3H, m
), 4.81 (1H, t), 6.60 (1H, S), 6
.. 75-7.40 (3H, m) Example 10 [2-(1
-Hydroxy)ethyl 2-hydroxy-3-isopropylamino)propoxybenzofuran]2-acetyl 2-hydroxy-3-isopropylamino)propoxybenzofuran 0.619 was added to the 1059 centrifuged supernatant of rabbit liver homogenate 80f1. The obtained enzyme fraction was mixed with coenzyme (NADPH) at pH 7.4 and temperature 37°C.
generation system) for 30 minutes.

2N一苛性ソーダ水溶液を加えて反応を停止し、生成物
をエーテルで抽出し、溶媒を留去し、えられた残渣をベ
ンゼンー石油エーテル( 1:1容量比)から再結晶し
て融点77〜81℃の白色粉末状の化合物を0.49え
た。
The reaction was stopped by adding 2N aqueous sodium hydroxide solution, the product was extracted with ether, the solvent was distilled off, and the resulting residue was recrystallized from benzene-petroleum ether (1:1 volume ratio) to give a solution with a melting point of 77-81. A white powdery compound was obtained at 0.49 °C.

このものは実施例3でえられたものと同じ元素分析値、
特性赤外線吸収スペクトル、Rf値およびδ値を示した
。実施例 11 〔2 −(1−ヒドロキシ)エチル− 7 −( 2
−ヒドロキシ−3−イソプロピルアミノ)プロポキシベ
ンゾフラン〕2−アセチル− 7 −( 2 −ヒドロ
キシ−3−イソプロピルアミノ)プロポキシベンゾフラ
ン0.619をエタノール100ゴに溶かした溶液をラ
ネーニツケル0.059とともに反応容器に入れ、水素
気流中で常圧下に約10時間振とうした。
This product has the same elemental analysis value as that obtained in Example 3,
Characteristic infrared absorption spectra, Rf values and δ values are shown. Example 11 [2-(1-hydroxy)ethyl-7-(2
-Hydroxy-3-isopropylamino)propoxybenzofuran]2-acetyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran 0.619 dissolved in 100 g of ethanol A solution of 0.059 Raney Nickel was placed in a reaction vessel. The mixture was shaken under normal pressure in a hydrogen stream for about 10 hours.

反応液をろ過して触媒を除き、ついで溶媒を減圧下に留
去した。えられた残渣をベンゼンー石油エーテル(1:
1容量比)から再結晶して融点77〜81℃の白色粉末
状の化合物を0.419えた。このものは実施例3でえ
られたものと同じ元素分析値、特性赤外線吸収スペクト
ル、Rf値およびδ値を示した。実施例 12 〔2−(α−ヒドロキシ)ベンジル− 7 −( 2−
ヒドロキシ−3−イソプロピルアミノ)プロポキシベン
ゾフラン〕2−ベンゾイル− 7 −( 2 −ヒドロ
キシ− 3 −イソプロピルアミノ)プロポキシベンゾ
フラン0.2f1をジオキサン20ゴに溶かし、氷冷下
に水素化ホウ素ナトリウム0.029を加え、ついで室
温下に1時間攪拌した。
The reaction solution was filtered to remove the catalyst, and then the solvent was distilled off under reduced pressure. The resulting residue was diluted with benzene-petroleum ether (1:
1 volume ratio) to yield 0.419 of a white powdery compound with a melting point of 77-81°C. This product showed the same elemental analysis values, characteristic infrared absorption spectrum, Rf value and δ value as those obtained in Example 3. Example 12 [2-(α-hydroxy)benzyl-7-(2-
Hydroxy-3-isopropylamino)propoxybenzofuran] 0.2f1 of 2-benzoyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran was dissolved in 20g of dioxane, and 0.029g of sodium borohydride was added under ice-cooling. The mixture was then stirred at room temperature for 1 hour.

えられた反応液を実施例1と同様に処理し、えられた残
渣をアセトンー石油エーテル( 1:1容量比)から再
結晶して融点135〜139℃の白色粉末状の化合物を
0.19えた。元素分析値:C2lH2,O4Nとして 理論値O:C7O.96H7.O9N3.94実測値%
:C7O.88H7.l6N3.79特性赤外線吸収ス
ペクトル:ν0H3330 νNH328O νC=Cl63O,l6OO,l59ORf値: 0.39 δ値: 1.12( 6H,d),2.70〜3.20( 3H
,m),3.40(3H,S),4.41(3H,m)
,5.96(IH,S),6.40( IH,S),6
.60〜7.60(8H,m)実施例 13〔2−ヒド
ロキシメチル− 7 −( 2 −ヒドロキシ−3−イ
ソプロピルアミノ)プロポキシベンゾフランおよびその
酢酸塩〕2−エトキシカルボニル− 7 −( 2 −
ヒドロキシ−3−イソプロピルアミノ)プロボキシベン
ゾフラン0.619をテトラヒドロフラン301neに
溶かし、氷冷下に水素化アルミニウムリチウム0.05
9を加え、ついで室温で3時間攪拌した。
The obtained reaction solution was treated in the same manner as in Example 1, and the obtained residue was recrystallized from acetone-petroleum ether (1:1 volume ratio) to obtain a white powdery compound with a melting point of 135-139°C. I got it. Elemental analysis value: C2lH2, O4N, theoretical value O: C7O. 96H7. O9N3.94 actual value%
:C7O. 88H7. l6N3.79 characteristic infrared absorption spectrum: ν0H3330 νNH328O νC=Cl63O,l6OO,l59ORf value: 0.39 δ value: 1.12 (6H, d), 2.70-3.20 (3H
, m), 3.40 (3H, S), 4.41 (3H, m)
,5.96(IH,S),6.40(IH,S),6
.. 60-7.60 (8H, m) Example 13 [2-hydroxymethyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran and its acetate] 2-ethoxycarbonyl-7-(2-
Dissolve 0.619 hydroxy-3-isopropylamino)proboxybenzofuran in 301 ml of tetrahydrofuran, and add 0.05 ml of lithium aluminum hydride under ice cooling.
9 was added and then stirred at room temperature for 3 hours.

えられた反応液を氷水150ゴ中に注ぎ、これを塩析下
酢酸エチルで抽出し、有機層を無水硫酸ナトリウムで脱
水後溶媒を減圧下に留去して淡黄色油状物の化合物0.
48Iをえた。えられた化合物0.489を実施例5と
同様に処理して融点144〜147℃の白色粉末状の酢
酸塩を0.49えた。
The resulting reaction solution was poured into 150 g of ice water, extracted with ethyl acetate under salting out, and the organic layer was dehydrated over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow oily compound with 0.0%.
I got 48I. 0.489 of the obtained compound was treated in the same manner as in Example 5 to obtain 0.49 of acetate in the form of a white powder with a melting point of 144-147°C.

元素分析値:Cl7H2,O6Nとして 理論値%:C6O.l6H7.43N4.l3実測値O
:C59.87H7.2lN4.38実施例 14〔2
−(1−ヒドロキシ)エチル− 7 −( 2 ーヒ
ドロキシ−3−イソプロピルアミノ)プロポキシベンゾ
フラン〕2−アセチル− 7 −( 2 −ヒドロキシ
− 3 −イソプロピルアミン)プロポキシベンゾフラ
ン0.619とアルミニウムイソプロポキシド0.21
9をイソプロパノール30!Neに溶かし加熱攪拌した
Elemental analysis value: Cl7H2, theoretical value % as O6N: C6O. l6H7.43N4. l3 Actual value O
:C59.87H7.2lN4.38 Example 14 [2
-(1-Hydroxy)ethyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran]2-acetyl-7-(2-hydroxy-3-isopropylamine)propoxybenzofuran 0.619 and aluminum isopropoxide 0. 21
9 to isopropanol 30! It was dissolved in Ne and stirred with heating.

この間生成するアセトンを留去し、イソプロパノールを
適宜滴下しながら還流をつづけた。アセトンが留去しな
くなつた時点で反応液を氷水中にあけ酢酸エチルエステ
ルで抽出した。溶媒を減圧留去し、残渣をベンゼンー石
油エーテル(3:2容量比)から再結晶して融点77〜
81℃の白色粉末状の化合物を0.51gえた。このも
のは実施例3でえられたものと同じ元素分析値、特性赤
外線吸収スペクトル、Rf値およびδ値を示した。実施
例 15実施例1〜9および12〜13でえられた各化
合物を活性成分として用い、かつ活性成分とキヤリヤー
成分を下記のごとき割合で混合し、えられた混合物をカ
プセルに充填してカプセル剤をえた。
During this time, acetone produced was distilled off, and reflux was continued while dropping isopropanol as needed. When acetone was no longer distilled off, the reaction solution was poured into ice water and extracted with ethyl acetate. The solvent was distilled off under reduced pressure, and the residue was recrystallized from benzene-petroleum ether (3:2 volume ratio) to give a melting point of 77~
0.51g of a white powdery compound having a temperature of 81°C was obtained. This product showed the same elemental analysis values, characteristic infrared absorption spectrum, Rf value and δ value as those obtained in Example 3. Example 15 Each compound obtained in Examples 1 to 9 and 12 to 13 was used as an active ingredient, and the active ingredient and carrier ingredient were mixed in the following proportions, and the resulting mixture was filled into capsules. I got some medicine.

実施例 16 実施例1〜9および12〜13でえられた各化合物を活
性成分として用い、これを生理食塩水に0.25重量%
の割合で溶解して注射薬を調製した。
Example 16 Each compound obtained in Examples 1 to 9 and 12 to 13 was used as an active ingredient, and 0.25% by weight of this was added to physiological saline.
Injections were prepared by dissolving the mixture in the following proportions:

試験例 〔実験1〕 供試動物として麻酔ラツトを用い、イソプロテレノール
負荷による血圧降下に対する前記実施例1〜3および6
〜9でえられた化合物(以下、化合物1〜3および6〜
9という)の抑制作用を調べた。
Test Example [Experiment 1] Using anesthetized rats as test animals, the above-mentioned Examples 1 to 3 and 6 were conducted on blood pressure reduction due to isoproterenol loading.
- Compounds obtained in 9 (hereinafter referred to as compounds 1-3 and 6-
9) was investigated.

イソプロテレノールの投与量ぱ1μf!/Kfとし、被
検薬物は静脈内注射により投与した。比較のためにアド
レナリン性β一受容体遮断剤として通常用いられている
プロプラノロール(PrOpranOlOl)について
も同様な実験を行なつた。
The dose of isoproterenol is 1 μf! /Kf, and the test drug was administered by intravenous injection. For comparison, a similar experiment was conducted using propranolol (PrOpranOlOl), which is commonly used as an adrenergic β-receptor blocker.

結果を第1表に示す。The results are shown in Table 1.

第1表において抑制作用は50%抑制値(ED5O)と
して示した。〔実験2〕 マウスを用いて化合物1〜3および6〜9の急性毒性(
LD5O)を調べた。
In Table 1, the inhibitory effect is shown as 50% inhibition value (ED5O). [Experiment 2] Acute toxicity of compounds 1 to 3 and 6 to 9 (
LD5O) was investigated.

被検薬物は生理食塩水溶液として静脈内投与した。比較
のためにプロプラノロールについても同様な実験を行な
つた。
The test drug was administered intravenously as a physiological saline solution. For comparison, a similar experiment was conducted with propranolol.

前記実験1〜2でえられたED5O(5LD50から治
癒係数(LD5O/ED,O)および強度比(プロプラ
ノールの冶癒係数を1としたばあいの相対比)を求めた
The healing coefficient (LD5O/ED,O) and strength ratio (relative ratio when the healing coefficient of propranol is set to 1) were determined from the ED5O (5LD50) obtained in Experiments 1 and 2 above.

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ (式中、Rは水素原子、低級アルキル基またはフェニル
基、R^1は低級アルキル基であり、置換プロポキシ基
はベンゾフラン環の3、4、5、6または7位の任意の
位置に置換している)で示されるベンゾフラン誘導体お
よびその酸付加塩。 2 2−(1−ヒドロキシ)エチル−7−(2−ヒドロ
キシ−3−sec−ブチルアミノ)プロポキシベンゾフ
ランである特許請求の範囲第1項記載の化合物。 3 2−(1−ヒドロキシ)エチル−7−(2−ヒドロ
キシ−3−tert−ブチルアミノ)プロポキシベンゾ
ランである特許請求の範囲第1項記載の化合物。 4 2−(1−ヒドロキシ)エチル−7−(2−ヒドロ
キシ−3−イソプロピルアミノ)プロポキシベンゾフラ
ンである特許請求の範囲第1項記載の化合物。
[Claims] 1 General formula ▲ Numerical formula, chemical formula, table, etc. benzofuran derivatives (substituted at any position of the 3rd, 4th, 5th, 6th or 7th ring) and acid addition salts thereof. 2. The compound according to claim 1, which is 2-(1-hydroxy)ethyl-7-(2-hydroxy-3-sec-butylamino)propoxybenzofuran. 3. The compound according to claim 1, which is 2-(1-hydroxy)ethyl-7-(2-hydroxy-3-tert-butylamino)propoxybenzolan. 4. The compound according to claim 1, which is 2-(1-hydroxy)ethyl-7-(2-hydroxy-3-isopropylamino)propoxybenzofuran.
JP51000351A 1975-10-20 1976-01-01 benzofuran derivatives Expired JPS5951547B2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP51000351A JPS5951547B2 (en) 1976-01-01 1976-01-01 benzofuran derivatives
CA257,342A CA1089866A (en) 1975-10-20 1976-07-20 Benzofuran derivatives, preparation thereof and pharmaceutical compositions thereof
GB3161576A GB1502248A (en) 1975-10-20 1976-07-29 Benzofuran derivatives preparation thereof and pharmaceutical compositions thereof
DE19762635064 DE2635064C2 (en) 1975-10-20 1976-08-04 Medicaments containing a 2- (1-hydroxyethyl) benzofuran derivative, 2- (1-hydroxyethyl) benzofuran derivatives as such and processes for their preparation
CH997876A CH628338A5 (en) 1975-10-20 1976-08-05 Process for the preparation of benzofuran derivatives
FR7624676A FR2328463A1 (en) 1975-10-20 1976-08-12 NEW BENZOFURANNE DERIVATIVES USEFUL IN PARTICULAR AS ADRENERGIC B-BLOCKERS AND THEIR PREPARATION PROCESS
BE169780A BE845156A (en) 1975-10-20 1976-08-13 NEW BENZOFURANNE DERIVATIVES USEFUL IN PARTICULAR AS BETA-ADRENERGIC BLOCKERS AND THEIR PREPARATION PROCESS
NL7610426A NL7610426A (en) 1975-10-20 1976-09-20 PROCESS FOR PREPARING BENZOFURANS.
CH529981A CH633785A5 (en) 1975-10-20 1981-08-17 Process for the preparation of benzofuran derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51000351A JPS5951547B2 (en) 1976-01-01 1976-01-01 benzofuran derivatives

Publications (2)

Publication Number Publication Date
JPS5283733A JPS5283733A (en) 1977-07-12
JPS5951547B2 true JPS5951547B2 (en) 1984-12-14

Family

ID=11471407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51000351A Expired JPS5951547B2 (en) 1975-10-20 1976-01-01 benzofuran derivatives

Country Status (1)

Country Link
JP (1) JPS5951547B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573196A (en) * 1983-01-19 1986-02-25 Communications Intelligence Corporation Confusion grouping of strokes in pattern recognition method and system
JP4952438B2 (en) * 2007-08-21 2012-06-13 パナソニック株式会社 Thermal fuse

Also Published As

Publication number Publication date
JPS5283733A (en) 1977-07-12

Similar Documents

Publication Publication Date Title
Crowther et al. . beta.-Adrenergic blocking agents. II. Propranolol and related 3-amino-1-naphthoxy-2-propanols
US4423044A (en) 3,4-Dihydro-5H-2,3-benzodiazepine derivatives and pharmaceutical use thereof
US4261895A (en) Alkanoyl-proline derivatives and homologues thereof
JP2637737B2 (en) New drugs
IL36237A (en) Substituted benzylimidazolidinones,their preparation and pharmaceutical compositions containing them
EP1641758B1 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
CA1288102C (en) Pyridine derivatives, their preparation and their use
US5480894A (en) 3-hydroxypyridin-4-one derivatives as chelating agents
US3120551A (en) 5-(4-biphenylyl)-3-methylvaleric acid and functional derivatives thereof
CA1149819A (en) Process for the manufacture of new amines
US4336268A (en) Cyclohexene derivative analgesics
US4094987A (en) 2-(3-m-hydroxy-phenyl-1-substituted-3-pyrrolidinyl)-ethanols
US2857384A (en) New pyridazone compounds
JPS5951547B2 (en) benzofuran derivatives
US3830806A (en) Derivatives of 1-phenoxy-3-amino-propan-2-ol
US4272533A (en) N-Phenylindoline derivatives, and pharmaceutical compositions containing them
JPS63183542A (en) Substituted octahydrophenanthrene and composition of same
JPS5849369A (en) Novel imidazole compound, manufacture and analgesic antipuretic antiinflammatory drug containing same as major component
US3960959A (en) N,N'-bis{6-[(3,4-dihydroxyphenyl)alkylamino]-hexyl}hexamethylenediamines and the salts thereof
US4663334A (en) Heteroaromatic acetylenes useful as antihypertensive agents
EP0038298B1 (en) Isoxazolyl indolamines
US3943257A (en) 4-Alkyl-4-naphthyl butenes
US3073840A (en) Benz[d]soxazole derivatives
US3467710A (en) Beta-(4- or 5-phenyl-1-naphthalene) ethylamines
US4007207A (en) Alkyl substituted-4-oxo-cyclopenta benzopyrans